Which genetic determinants should be considered for tacrolimus dose optimization in kidney transplantation? A combined analysis of genes affecting the CYP3A locus

Therapeutic Drug Monitoring

Volumn 37, Issue 3, 2015, Pages 288-295

  Bruckmueller, Henrike ^a   Werk, Anneke Nina ^a   Renders, Lutz ^b   Feldkamp, Thorsten ^a   Tepel, Martin ^c   Borst, Christoffer ^c   Caliebe, Amke ^a   Kunzendorf, Ulrich ^a   Cascorbi, Ingolf ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

dose optimization; kidney transplantation; modeling; pharmacogenetics; tacrolimus

Indexed keywords

CREATININE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 REDUCTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PREGNANE X RECEPTOR; TACROLIMUS; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT; POR PROTEIN, HUMAN; STEROID RECEPTOR;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CONCENTRATION RESPONSE; CREATININE BLOOD LEVEL; DANISH CITIZEN; DENMARK; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; GENE LOCUS; GENETIC VARIABILITY; GENOTYPE; GERMAN (CITIZEN); GERMANY; HEREDITY; HOMOZYGOSITY; HUMAN; KIDNEY TRANSPLANTATION; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MINIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PRIORITY JOURNAL; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; TIME TO MAXIMUM PLASMA CONCENTRATION; DRUG MONITORING; GENETICS; PROCEDURES;

CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG MONITORING; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR ALPHA; RECEPTORS, STEROID; TACROLIMUS;

EID: 84929957158     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000142     Document Type: Article

References (29)

1. Benkali K, Premaud A, Picard N, e t al. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet. 2009;48:805-816.
2. Gijsen VM, Madadi P, Dube MP, et al. Tacrolimus-induced nephrotoxicity and genetic variability: a review. Ann Transplant. 2012;17:111-121.
3. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29:404-430.
4. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383-391.
5. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 2001;11:773-779.
6. Renders L, Frisman M, Ufer M, et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther. 2007;81:228-234.
7. Wang D, Guo Y, Wrighton SA, et al. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 2011;11:274-286.
8. Elens L, van Schaik RH, Panin N, et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics. 2011;12:1383-1396.
9. Elens L, Capron A, van Schaik RH, et al. Impact of CYP3A4 22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. Ther Drug Monit. 2013;35:608-616.
10. Barraclough KA, Isbel NM, Lee KJ, et al. NR1I2 polymorphisms are related to tacrolimus dose-Adjusted exposure and BK viremia in adult kidney transplanta tion. Transplantation. 2012;94:1025-1032.
11. Klein K, Thomas M, Winter S, et al. PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo. Clin Pharmacol Ther. 2012;91: 1044-1052.
12. Zhang JJ,Zhang H,Ding XL,et al. Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers Eur J Clin Pharmacol. 2013 69, 807-812.
13. Elens L, Hesse link DA, Bouamar R, et al. Impact of POR 28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients. Ther Drug Monit. 2014;36:71-79.
14. Taylor PJ, Jones A, Bal derson GA, et al. Sensitive, specific quantitative analysis of tacrolimus (FK506) in blood by liquid chromatographyelectrospray tandem mass spectrometry. Clin Chem. 1996;42:279-285.
15. Faul F, Erdfe lder E, Buchner A, et al. Statistical power analyses using G Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41:1149-1160.
16. Anglicheau D, Legendre C, Beau ne P, et al. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics. 2007;8:835-849.
17. Hesselink DA, van Schaik RH, van dH I, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003;74:245-254.
18. Thervet E, Loriot MA, Barbier S, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87: 721-726.
19. Vannaprasaht S, Reungjui S, Supanya D, et al. Personalized tacrolimus doses deter mined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation. Clin Ther. 2013;35:1762-1769.
20. Santoro AB, Struchiner CJ, Felipe CR, et al. CYP3A5 genotype, but not C YP3A41b, CYP3A4 22, or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients. Clin Pharmacol Ther. 2013;94:201-202.
21. Shi Y, Li Y, Tang J, et al. Influence of CY P3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. Gene. 2013;512:226-231.
22. Werk AN, Lefeldt S, Bruckmueller H, et al. Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance. Clin Pharmacol Ther. 2014;95:416-422.
23. Barker DF, Hostikka SL, Zhou J, et al. Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science. 1990;248: 1224-1227.
24. Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev. 2002;23: 687-702.
25. Oneda B, Crettol S, Jaquenoud SE, et al. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet Genomics. 2009;19: 87 7-883.
26. Lunde I, Bremer S, Midtvedt K, et al. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. Eur J Clin Pharmaco l. 2014;70:685-693.
27. Elens L, Bouamar R, Hesselink DA, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem. 2011;57:1574-1583.
28. Li L, Li CJ, Zheng L, et al. Tacrolimus dosing in Chinese renal transplant recipients: a population-based pharmacogenetics study. Eur J Clin Pharmacol. 2011;67:787-795.
29. van Gelder T, van Schaik RH, Hesselink DA. Practicability of pharmacogenetics in transplantation medicine. Clin Pharmacol Ther. 2014;95: 262-264.